What is MDGL's current stock price?

MDGL (Madrigal Pharmaceuticals, Inc.) is currently trading at $517.26 with a market cap of $11.93B.

What sector is Madrigal Pharmaceuticals, Inc. in?

Madrigal Pharmaceuticals, Inc. (MDGL) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is MDGL a good stock to buy?

Analysts have a Buy consensus on MDGL with a price target of $731.25. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

MDGL Madrigal Pharmaceuticals, Inc.

Healthcare

$517.26+0.71%ClosedMarket Cap: $11.93B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

27.63

P/S

10.53

EV/EBITDA

-41.86

DCF Value

$2,832.51

FCF Yield

-2.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

93.1%

Operating Margin

-27.7%

Net Margin

-27.3%

ROE

-50.2%

ROA

-25.2%

ROIC

-35.2%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$311.3M	$-94.4M	$—
Q4 null	$321.1M	$-58.6M	$—
FY null	$958.4M	$-288.3M	$—
Q3 null	$287.3M	$-114.2M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$731.25

Target (Median)

$679.00

Target Range

$571.00 - $964.00

3 Strong Buy11 Buy2 Hold0 Sell0 Strong Sell

Truist SecuritiesBuy

2026-05-13

Canaccord GenuityBuy

2026-05-07

Evercore ISI GroupOutperform

2026-05-07

HC Wainwright & Co.Buy

2026-05-06

B of A SecuritiesNeutral

2026-02-20

Trading Activity

Insider Trades

View All

Levy Richard Sdirector

SellFri May 22

Levy Richard Sdirector

SellFri May 22

Levy Richard Sdirector

SellFri May 22

Levy Richard Sdirector

SellFri May 22

Levy Richard Sdirector

SellFri May 22

Related AI Research

8-K EventMay 6, 2026

MDGL files 8-K — Item 2.02 Results of Operations

Madrigal Pharmaceuticals, Inc.

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

-1.04

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Peers

BAX

CAI

RNA